Dogwood Offloads Antiviral Assets in $100M-Cap Licensing Deal

Dogwood Therapeutics is executing a deliberate pipeline consolidation, transferring full development and commercialization responsibility for its antiviral candidates IMC-1 and IMC-2 to PRIDCor Therapeutics, LLC -- a move that redirects internal resources toward its NaV 1.7 inhibitor Halneuron® and the recently in-licensed SP16. For CDMOs and contract research organizations currently supporting antiviral programs, the shift in sponsorship from a NASDAQ-listed entity to a clinical-stage LLC carries direct implications for contract continuity and future development financing structures.

Under the agreement, PRIDCor assumes full responsibility for financing, executing development, commercialization, and intellectual property maintenance for both IMC-1 and IMC-2 across all indications, including fibromyalgia and Long-COVID. In return, Dogwood retains a tiered royalty on net sales of up to 15%, a 9% interest in all future capital raised by PRIDCor to advance IMC-1 or IMC-2, and entitlement to future partnership-related development and regulatory milestone payments. Total potential payments to Dogwood are capped at $100 million.

Pipeline focus and downstream considerations: Dogwood's decision to in-license SP16 -- administered via intravenous formulation -- as a complement to Halneuron® signals a tightening of therapeutic focus on chemotherapy-induced pain and neuropathy. Halneuron® holds FDA Fast Track designation for chemotherapy-induced neuropathic pain (CINP) and is currently in Phase 2b development. Manufacturing teams supporting IV formulation development for SP16 should anticipate GMP requirements consistent with sterile injectable programs under 21 CFR Part 211.

Dogwood has also disclosed that payments received under this agreement that qualify as Upfront or Milestone Payments under the terms of contingent value rights (CVRs) issued October 17, 2024, will be directed to the CVR rights agent for distribution to CVR holders. Regulatory and legal affairs teams at similarly structured clinical-stage companies should note this as a structural precedent for asset monetization tied to existing shareholder instruments.

Source: Dogwood Therapeutics, Inc. press release via GlobeNewswire, April 23, 2026.